Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 12, 2021 at 06:36 pm EST
Nymox Pharmaceutical Corporation reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 3.3 million compared to USD 4.16 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.06 a year ago. Diluted loss per share from continuing operations was USD 0.04 compared to USD 0.06 a year ago.
For the nine months, net loss was USD 9.73 million compared to USD 9.71 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.13 a year ago. Diluted loss per share from continuing operations was USD 0.12 compared to USD 0.13 a year ago.